Profile data is unavailable for this security.
About the company
Jiangsu Jibeier Pharmaceutical Co Ltd is a China-based company primarily engaged in the research and development and manufacturing of drugs. The Company’s main products include tablets, capsules, and eye drops. Tablet products mainly include Leucogen Tablets, Nitrendipine and Atenolol Tablets, Aceclofenac Enteric-coated tablets, and Asarone Tablets. Capsule products mainly include Yupingfeng Jiaonang and Yiganling Jiaonang. Eye drop products include Gatifloxacin Eye Drops and Lomefloxacin Hydrochloride Eye Drops. The Company also focuses on the research and development of innovative drugs for the treatment of depression, tumors, and gastric diseases. The Company mainly conducts its businesses within domestic market.
- Revenue in CNY (TTM)957.76m
- Net income in CNY241.67m
- Incorporated2001
- Employees1.33k
- LocationJiangsu Jibeier Pharmaceutical Co LtdHigh-tech Industry Development ZoneZhenjiang 212000ChinaCHN
- Phone+86 51 188898101
- Fax+86 51 188889488
- Websitehttps://www.jbepharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.68bn | 295.36m | 5.46bn | 1.81k | 18.53 | 3.26 | -- | 3.24 | 0.6709 | 0.6709 | 3.83 | 3.81 | 0.5327 | 1.42 | 6.00 | 931,293.10 | 9.11 | 6.11 | 16.09 | 10.86 | 68.68 | 67.05 | 17.10 | 10.32 | 0.5475 | 19.04 | 0.2332 | 49.73 | 9.15 | 10.20 | 36.61 | 26.46 | -13.82 | 38.88 |
| Jiangsu Jibeier Pharmaceutical Co Ltd | 957.76m | 241.67m | 5.75bn | 1.33k | 23.85 | 2.44 | -- | 6.00 | 1.21 | 1.21 | 4.79 | 11.82 | 0.3733 | 3.26 | 3.71 | 721,747.90 | 9.37 | 8.99 | 10.04 | 9.78 | 87.92 | 88.72 | 25.11 | 23.97 | 7.17 | -- | 0.0092 | 32.97 | 4.14 | 10.57 | 0.1095 | 14.20 | 42.01 | -- |
| Jiangsu Lianhuan Pharmaceutical Co. Ltd | 2.60bn | -43.60m | 6.02bn | 1.39k | -- | 4.51 | -- | 2.32 | -0.1527 | -0.1527 | 9.10 | 4.68 | 0.7279 | 3.28 | 4.16 | 1,872,001.00 | -0.8081 | 5.51 | -1.74 | 10.75 | 36.36 | 51.36 | -1.11 | 7.34 | 0.7909 | 1.88 | 0.4592 | 30.61 | -0.6275 | 10.86 | -37.66 | 1.09 | 1.85 | 1.16 |
| Holder | Shares | % Held |
|---|---|---|
| Caitong Fund Management Co., Ltd.as of 30 Jun 2025 | 2.31m | 1.37% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 2.22m | 1.32% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 319.19k | 0.19% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 282.56k | 0.17% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 176.41k | 0.11% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 175.98k | 0.10% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 93.07k | 0.06% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 73.32k | 0.04% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 69.10k | 0.04% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025 | 65.45k | 0.04% |
